Research Paper Volume 16, Issue 1 pp 872—910
XRCC1: a potential prognostic and immunological biomarker in LGG based on systematic pan-cancer analysis
Figure 5. We utilized the UALCAN tool to compare the expression status of XRCC1 phosphoprotein (NP_006288.2, S234, S241, S266, S268, S447, S461, S475, and T453 sites) between primary tissue of specific tumors and normal tissue from CPTAC database. The schematic diagram of XRCC1 protein (A) demonstrated the phosphoprotein sites with positive results. We also enriched the box plots with different tumors containing breast cancer (B), clear cell RCC (C), COAD (D), LUAD (E), GBM (F), UCEC (G), PAAD (H), ovarian cancer (I), HNSC (J).